Geneos Wealth Management’s Lucid Diagnostics LUCD Stock Holding History

Geneos Wealth Management’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,550	Closed	-$24.2K	–	3131
2024 Q4	$24.2K	Sell	29,550 -4,300	-13%	-$3.79K	﹤0.01%	1629
2024 Q3	$27.8K	Hold	33,850	–	–	﹤0.01%	1426
2024 Q2	$27.8K	Hold	33,850	–	–	﹤0.01%	1251
2024 Q1	$27.4K	Hold	33,850	–	–	﹤0.01%	1265
2023 Q4	$47.7K	Hold	33,850	–	–	﹤0.01%	1079
2023 Q3	$39.6K	Hold	33,850	–	–	﹤0.01%	1144
2023 Q2	$47.1K	Hold	33,850	–	–	﹤0.01%	1097
2023 Q1	$47.4K	Hold	33,850	–	–	﹤0.01%	1098
2022 Q4	$46K	Sell	33,850 -7,000	-17%	-$12.6K	﹤0.01%	1086
2022 Q3	$62K	Sell	40,850 -1,600	-4%	-$3.98K	﹤0.01%	956
2022 Q2	$98K	Sell	42,450 -20,000	-32%	-$44.4K	﹤0.01%	1015
2022 Q1	$209K	Buy	+62,450	New	+$228K	0.01%	788

Other funds holding LUCD

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geneos Wealth Management's LUCD Position: Q1 2025 in Review

Geneos Wealth Management sold out of Lucid Diagnostics (LUCD) in Q1 2025, closing a stake of 29,550 shares — an estimated $24.2K sold.

Geneos Wealth Management first reported a position in LUCD in Q1 2022 and held it in 12 quarters. The position peaked at $209K in Q1 2022. 49 funds tracked by Wall St. Rank hold LUCD as of Q1 2025.

Geneos Wealth Management reported no remaining Lucid Diagnostics position as of Q1 2025 after selling out during the quarter.
Geneos Wealth Management sold 29,550 Lucid Diagnostics shares in Q1 2025, an estimated $24.2K.
Geneos Wealth Management first reported a position in Lucid Diagnostics in Q1 2022 and held it in 12 quarters.
Geneos Wealth Management's Lucid Diagnostics position peaked at $209K in Q1 2022.
49 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2025.

Based on Geneos Wealth Management's 13F filing for Q1 2025, filed 8 May 2025.